Analyst Group has entered into an agreement with Circio Holding on commissioned research, including e.g. equity research reports with quarterly updates, comments on press releases and CEO interviews.
First Mover Advantage in the Next Phase of Genetic Medicine
Circio Holding (”Circio” or ”the Company”) addresses a key limitation in gene therapy: insufficient and short-lived protein production. The Company’s platform circVec is based on circular RNA and has demonstrated materially higher protein output than conventional linear RNA in preclinical studies. Developed within established AAV delivery systems, circVec has the potential to enable lower vector doses, improving the safety profile and reducing manufacturing costs. This creates a compelling opportunity for pharmaceutical partners to both address new unmet indications and upgrade existing gene therapies through a plug-in expression enhancement, potentially extending product lifecycles without altering the delivery vector. With estimated funding into Q2-27, Circio has runway to reach key disease-model efficacy readouts in H2-26, rep-resenting catalysts for partnering activity. Based on a platform-focused rNPV framework, we derive a present value of NOK 2.03 per share in a Base scenario.
Read the equity research report here
About Analyst Group: One of Sweden's leading analysis houses with a focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of an equity research report on Circio Holding. Readers may assume that Analyst Group has received compensation for making the equity research report. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation, or anything else that could be considered a subjective assessment.